Consumer health products containing cannabinoids and deemed unapproved drugs in the US aren’t limited to products marketed as dietary supplements. The Food and Drug Administration has warned a contract manufacturer and another firm about making OTC drugs with cannabinoids.
The firms, BioLyte Laboratories LLC and Honest Globe Inc., also were advised by the FDA’s Office of Regulatory Affairs Division of Pharmaceutical Quality Operations that listing cannabinoids as inactive ingredients...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?